<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132980">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370629</url>
  </required_header>
  <id_info>
    <org_study_id>6621-049</org_study_id>
    <secondary_id>EP01029.004</secondary_id>
    <nct_id>NCT01370629</nct_id>
  </id_info>
  <brief_title>Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)</brief_title>
  <official_title>A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiome Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiome Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional prospective study is a post-authorization safety study (PASS) of
      vernakalant conducted to collect information about normal conditions of use and appropriate
      dosing, and to quantify possible medically significant risks associated with the use of
      vernakalant in real-world clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing significant hypotension</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing significant ventricular arrhythmia</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing significant atrial flutter</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing significant bradycardia</measure>
    <time_frame>Start (baseline) of first vernakalant infusion up to 24 hours after the last infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who are converted to sinus rhythm for at least one minute</measure>
    <time_frame>Up to 90 minutes after the start (baseline) of first infusion of vernakalant</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants treated with vernakalant IV in acute care and inpatient hospital settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vernakalant</intervention_name>
    <description>Prescribed at the discretion of the physician in accordance with their usual practice</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>BRINAVESSÂ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants treated with intravenous vernakalant in acute care and inpatient hospital
        settings per usual care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be treated with intravenous vernakalant, independently of this study

          -  Participant and/or legal guardians willing to provide informed consent and/or
             informed assent according to local regulations

        Exclusion Criteria:

        - Enrollment in an investigational drug or device clinical trial in the 30 days prior to
        study enrolment. Participation in another non-interventional drug or device study or
        registry is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Steen Juul-Moller, Dr</last_name>
    <email>sjuul-moller@cardiome.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St-Vincenz Krankenhaus</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skanes Universistetssjukhus</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 29, 2016</lastchanged_date>
  <firstreceived_date>June 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
